2 active not recruiting, 2 recruiting, 1 completed, 1 not yet recruiting. 7 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Active not recruiting 2, Recruiting 2, Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Peripheral T Cell Lymphoma: new trials by email Literature Review of Peripheral T Cell Lymphoma trials Research Report on Peripheral T Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy golidocitinib, Placebo - Peripheral T Cell Lymphoma | Phase 3 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 68 | 2026-02-15 | 2026-02-24 |
| A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma Cidabenamine, Azacitidine - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 40 | 2026-02-01 | 2026-02-05 |
| A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma Linperlisib - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai YingLi Pharmaceutical Co. Ltd. | 606 | 2024-09-10 | 2024-08-12 |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Belinostat Injection, Pralatrexate Injection, CHOP - Peripheral T Cell Lymphoma | Phase 3 | Active not recruiting | Acrotech Biopharma Inc. | 504 | 2023-10-04 | 2026-10-15 |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL Mitoxantrone Hydrochloride Liposome Injection, Chidamide - Peripheral T Cell Lymphoma | Phase 3 | Active not recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 193 | 2021-04-13 | 2025-05-31 |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients chidamide, cyclophosphamide, liposomal doxorubicin - Peripheral T Cell Lymphoma | Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 174 | 2017-02-01 | 2017-01-18 |
| Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma CHOP21, VIP/ABVD, Radiotherapy consolidation - Peripheral T Cell Lymphoma | Phase 3 | Completed | University Hospital, Grenoble | 95 | 1995-01-01 | 2009-09-09 |
Lymphoma, T-Cell, Peripheral (7)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, T-Cell (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7)
Cyclophosphamide (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2) · Prednisone (2) · Vincristine (2) · 10-propargyl-10-deazaaminopterin (1) · Azacitidine (1) · CHOP protocol (1) · Doxorubicin (1) · belinostat (1) · liposomal doxorubicin (1)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Acrotech Biopharma Inc. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Nanfang Hospital, Southern Medical University (1) · Shanghai YingLi Pharmaceutical Co. Ltd. (1) · University Hospital, Grenoble (1)
China (4) · Canada (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1) · United States (1)
Ru Feng, M.D. (1) · Uma Srinivas Atmuri, MPharm, MS (1)